学院教职员

教学人员

杨祖耀教授

Prof. Joey Zu-yao YANG

BMedSc (PKU), MMedSc (PKU), PhD (CUHK)

助理教授

电邮: zyang@cuhk.edu.hk

 

ORCID: 0000-0003-2386-2431

个人简介

杨祖耀教授在北京大学获得预防医学学士学位和流行病学及生物统计学硕士学位,在香港中文大学获得公共卫生博士学位。他擅长流行病学方法,尤其是系统回顾,并大量参与本科生和研究生课程的流行病学课程教学。杨教授撰写了60多篇论文,其中包括发表在《英国医学杂志》和《内科年鉴》等备受推崇的期刊上。他还担任着20多份国际期刊的同行评审。

研究方向

  • 主要慢性病的预后因素和治疗效果

  • 心血管疾病的风险因素和基层预防

  • 循证医学:过度诊断和过度治疗

  • 研究废料

近期获资助研究项目

  • Estimating the magnitude of over-diagnosis of thyroid cancer and prostate cancer in mainland China: a modelling study based on national registry data. The Chinese University of Hong Kong Direct Grant for Research 2019/2020, HK$ 62,000, 30 June 2020 - 29 June 2021, the principal applicant

  • Relationship between skin rash and clinical outcomes in advanced pancreatic cancer treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. Health and Medical Research Fund, Food and Health Bureau, 2017.07.24-2018.07.23, HK$ 431,260.00, the principal applicant

  • Faculty Postdoctoral Fellowship Scheme, the Chinese University of Hong Kong, HK$360,000.00, 2014.04-2016.04, the principal applicant

  • The concordance of KRAS, BRAF, PIK3CA, and PTEN status between primary tumors and corresponding metastases in patients with colorectal cancer: a systematic review and meta-analysis, Health and Medical Research Fund, Food and Health Bureau, 2015.07.01-2016.06.30, HK$ 356,664.00, the 2nd applicant

  • The predictive biomarkers for EGFR tyrosine kinase inhibitors treatment in patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials, Health and Medical Research Fund, Food and Health Bureau, 2014.01.01-2014.12.31, HK$ 214,416.00, the 2nd applicant

  • The association between molecular biomarkers in EGFR downstream signaling pathway and clinical outcomes of cetuximab treatment in patients with metastatic colorectal cancer, Health and Medical Research Fund, Food and Health Bureau, 2013.06.01-2016.05.31, HK$ 981,720.00, the 5th applicant

  • Design and evaluating a new model to determine whose cholesterol should be measured for primary prevention, National Natural Science Foundation of China, 2013.01.01-2016.12.31, RMB 850,000.00, the 7th applicant

部份学术文章

  1. Feng Q, Zhou A, Zou H, Ingle S, May MT, Cai W, Cheng CY, Yang Z (corresponding author), Tang J. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;366:I4179.

  2. Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer 2017;140(12):2805-2819.

  3. Yang Z, Fan H, Tang J. Guidance for modifying disease definition. JAMA Intern Med. 2017;177(12):1872-3.

  4. Yang ZY, Yu YY, Yuan JQ, Shen WX, Zheng DY, Chen JZ, Mao C, Tang JL. The prognostic value of phosphatase and tensin homolog negativity in breast cancer: a systematic review and meta-analysis of 32 studies with 4393 patients. Crit Rev Oncol Hematol 2016;101:40-9.

  5. Yang ZY, Scott CA, Mao C, Tang JL, Farmer AJ. Resistance exercise versus aerobic exercise for type 2 diabetes: a systematic review and meta-analysis. Sports Med 2014; 44(4):487-99.

  6. Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev 2014; 11:CD009948.

  7. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 2013; 133(8):1914-25.

  8. Yang ZY, Mao C, Tang JL. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2012; 366(8):767.

  9. Yang ZY, Shen WX, Hu XF, Zheng DY, Wu XY, Huang YF, Chen JZ, Mao C, Tang JL. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: meta-analysis. J Hematol Oncol 2012;5(1):52.

  10. Yang ZY, Mao C, Tang JL. Depression and Risk of Stroke. JAMA 2011; 306(23):2562-3.

Last Updated: 27 July 2020

© 香港中文大学2020 版权所有

  • Facebook - CUHK JC School of Public Health and Primary Care